Literature DB >> 12089368

Cardiac and renal effects of standard versus rigorous blood pressure control in autosomal-dominant polycystic kidney disease: results of a seven-year prospective randomized study.

Robert Schrier1, Kimberly McFann, Ann Johnson, Arlene Chapman, Charles Edelstein, Godela Brosnahan, Tevfik Ecder, Lyn Tison.   

Abstract

This study sought to investigate the cardiac and renal effects of rigorous versus standard BP control on autosomal-dominant polycystic kidney disease (ADPKD). A prospective, randomized, 7-yr study was performed to examine the effect of rigorous (<120/80 mmHg) versus standard (135-140/85-90 mmHg) BP control on left ventricular mass index (LVMI) and kidney function in 75 hypertensive ADPKD patients with left ventricular hypertrophy. LVMI was measured by echocardiogram at baseline and at 1 and 7 yr. Renal function was assessed by measuring serum creatinine and 24-h creatinine clearance every 6 mo for 3 yr, then annually for an additional 4 yr. The baseline characteristics were comparable in the two groups. During the study, average mean arterial pressure was 90 +/- 5 mmHg for the rigorous group and 101 +/- 4 mmHg for the standard group (P < 0.0001). The LVMI decreased by 21% in the standard group and by 35% in the rigorous group. A mixed model longitudinal data analysis revealed that rigorous BP control was significantly more effective in decreasing LVMI (P < 0.01). There was no statistically significant difference in renal function between the two groups. In conclusion, left ventricular hypertrophy, a major cardiovascular risk factor, was decreased to a significantly greater extent by rigorous than standard BP control. This finding has particular clinical importance because cardiovascular complications are the most common cause of death in ADPKD patients.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12089368     DOI: 10.1097/01.asn.0000018407.60002.b9

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  58 in total

1.  Hypertension in Autosomal Dominant Polycystic Kidney Disease: A Clinical and Basic Science Perspective.

Authors:  Shobha Ratnam; Surya M Nauli
Journal:  Int J Nephrol Urol       Date:  2010

2.  Blood pressure in early autosomal dominant polycystic kidney disease.

Authors:  Robert W Schrier; Kaleab Z Abebe; Ronald D Perrone; Vicente E Torres; William E Braun; Theodore I Steinman; Franz T Winklhofer; Godela Brosnahan; Peter G Czarnecki; Marie C Hogan; Dana C Miskulin; Frederic F Rahbari-Oskoui; Jared J Grantham; Peter C Harris; Michael F Flessner; Kyongtae T Bae; Charity G Moore; Arlene B Chapman
Journal:  N Engl J Med       Date:  2014-11-15       Impact factor: 91.245

3.  Geographic differences in the increasing ESRD rate have disappeared in Japan.

Authors:  Tamaki Wakamatsu-Yamanaka; Michio Fukuda; Ryo Sato; Takehiro Naito; Hiroyuki Togawa; Tatsuya Tomonari; Yoko Kato; Toshiyuki Miura; Masashi Mizuno; Tadashi Ichikawa; Sota Miyagi; Yuichi Shirasawa; Akinori Ito; Atsuhiro Yoshida; Genjiro Kimura
Journal:  Clin Exp Nephrol       Date:  2011-06-03       Impact factor: 2.801

Review 4.  The African American Study of Kidney Disease: do these results indicate that 140/90 mm hg is good enough?

Authors:  Mahboob Rahman; Ashraf El-Meanawy; Joseph Romanello
Journal:  Curr Hypertens Rep       Date:  2005-10       Impact factor: 5.369

Review 5.  Potential pharmacological interventions in polycystic kidney disease.

Authors:  Amirali Masoumi; Berenice Reed-Gitomer; Catherine Kelleher; Robert W Schrier
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 6.  Blood pressure level and kidney disease progression: do we really need to go to 130/80 mm Hg?

Authors:  Bassam G Abu Jawdeh; Mahboob Rahman
Journal:  Curr Hypertens Rep       Date:  2009-10       Impact factor: 5.369

7.  Prevalence of cardiovascular events in patients with autosomal dominant polycystic kidney disease.

Authors:  Imed Helal; Berenice Reed; Pamela Mettler; Kim Mc Fann; Oleksandra Tkachenko; Xiang-Dong Yan; Robert W Schrier
Journal:  Am J Nephrol       Date:  2012-10-04       Impact factor: 3.754

Review 8.  Autosomal dominant polycystic kidney disease and transplantation.

Authors:  Mariusz Niemczyk; Stanisław Niemczyk; Leszek Paczek
Journal:  Ann Transplant       Date:  2009 Oct-Dec       Impact factor: 1.530

9.  The HALT polycystic kidney disease trials: design and implementation.

Authors:  Arlene B Chapman; Vicente E Torres; Ronald D Perrone; Theodore I Steinman; Kyongtae T Bae; J Philip Miller; Dana C Miskulin; Frederic Rahbari Oskoui; Amirali Masoumi; Marie C Hogan; Franz T Winklhofer; William Braun; Paul A Thompson; Catherine M Meyers; Cass Kelleher; Robert W Schrier
Journal:  Clin J Am Soc Nephrol       Date:  2010-01       Impact factor: 8.237

10.  A young patient with a family history of hypertension.

Authors:  Aldo J Peixoto
Journal:  Clin J Am Soc Nephrol       Date:  2014-08-04       Impact factor: 8.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.